Valvular & structural heart disease
Screening for amyloidosis before aortic valve elective replacement: results from the SAVER study
Authors' conclusion
The SAVER approach is the first holistic screening method focusing on CA's multiorgan manifestations in AS.
Study context
- Population
- Aortic stenosis (AS) patients planned for transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR), 2021–2023405 (40%) flagged for potential cardiac amyloidosis (CA)
- Participants
- 1,001 patients
- Outcome
- Simple CA screening for AS patients (yield of confirmed CA; predictors of CA)
Main finding
As reported in the abstract
Confirmed cardiac amyloidosis
Further diagnostics due to screening
206
21%
Further diagnostics due to physician discretion
5
0.5%
Confirmed CA cases
17
2%
Observational data: associations, not effects.
Further findings
Predictors of CA (multiple regression)
| OR (95% CI) | ||
|---|---|---|
| Male sex | 23.8 (2.6–216.9) | |
| Carpal tunnel syndrome | 5.5 (1.4–22.0) | |
| Spinal stenosis | 4.1 (1.1–14.7) | |
| Heaviness or numbness of arms or legs | 3.8 (1.1–13.3) | |
| NT-proBNP | 6.7 (1.8–25.3) | |
| Sparkling myocardium | 4.8 (1.3–17.3) | |
| 0.050.21520Odds ratio (log scale) |
- Predictors of CA (multiple regression) — Optimized approach AUC
- 0.88 (95% CI 0.81-0.96)
Original publication
Screening for amyloidosis before aortic valve elective replacement: results from the SAVER study. Eur J Prev Cardiol. Published 22 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →